Peter Farmakis

Insider

First SEC filing: Jan. 27, 2017 · Latest: Jan. 27, 2017

On this page

Insider at

0 buys (P) 0 sells (S) Net: $0 + 2 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

No open-market trades on record; showing all filings.

Date	Ticker	Code	Shares	Price	Value	Owned after	Δ own	A/D	vs now
Feb. 2, 2017	JELD	A	23,096	—	—	23,096 Direct	—	Acquired	(price as of 2026-08-19)
Feb. 2, 2017	JELD	A	6,721	—	—	6,721 Direct	—	Acquired	(price as of 2026-08-19)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Options, RSUs and convertible securities reported on Form 4 Table II.

Date	Ticker	Security	Underlying	Exercise price	Expiration	Shares	A/D
Feb. 2, 2017	JELD	Stock Option (Right to Buy)	Common Stock (23,096)	$27.59	Feb. 2, 2027	23,096	Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Securities held when first becoming an insider, per SEC Form 3.

Date	Ticker	Security	Shares	Ownership
Jan. 27, 2017	JELD	Common Stock Option (Right to Buy)→ Common Stock (3,520)	3,520	Direct
Jan. 27, 2017	JELD	Common Stock Option (Right to Buy)→ Common Stock (3,520)	3,520	Direct
Jan. 27, 2017	JELD	Common Stock Option (Right to Buy)→ Common Stock (10,560)	10,560	Direct
Jan. 27, 2017	JELD	Class B-1 Stock Option (Right to Buy) [F6]→ Common Stock	—	Direct
Jan. 27, 2017	JELD	Class B-1 Stock Option (Right to Buy) [F6]→ Common Stock	—	Direct